Gastroenterology

Co-antibody combination tops golimumab, guselkumab in refractory IBD

A novel co-antibody combination therapy demonstrated superior efficacy over existing biologics, golimumab and guselkumab, in patients with refractory inflammatory bowel disease.

Upadacitinib, Infliximab Lead for Rapid Ulcerative Colitis Relief

Upadacitinib and infliximab emerge as frontrunners for rapid clinical response in ulcerative colitis, offering quicker symptom resolution than other biologics.

Genetic Biomarker Predicts Adverse Outcomes in IBD

A specific genetic biomarker is linked to increased risk of adverse outcomes, including surgery and hospitalisation, in both ulcerative colitis and Crohn's disease.

GLP-1RAs: No Increased Risk of Acute Pancreatitis vs. Sulfonylureas

A target trial emulation found no increased risk of all-cause or cause-specific acute pancreatitis with GLP-1RA initiation versus sulfonylureas.

Risankizumab Shows Efficacy in Refractory Crohn's Real-World Data

Real-world data indicate risankizumab is effective in highly refractory Crohn's disease, including patients with prior advanced therapy exposure.

AI System Achieves Over 90% Accuracy in Colonoscopy Surveillance

An AI system accurately selected appropriate colonoscopy surveillance intervals in over 90% of cases, potentially streamlining post-polypectomy care.

AI in Gastroenterology: Benefits, Risks, and Safeguards for Practice

Artificial intelligence (AI) offers potential for enhanced diagnostic accuracy and efficiency in gastroenterology, but requires careful implementation.

Peptide-Based Preparations May Invert Colonoscopy Risk Profile

Novel peptide-based preparations for colonoscopy may mitigate the risks associated with inadequate bowel cleansing, potentially inverting the traditional risk-benefit profile.

Real-World Data Confirm Risankizumab Efficacy in Crohn's Disease

New real-world data from the ENEIDA registry and other analyses confirm risankizumab's effectiveness in refractory Crohn's disease, including endoscopic outcomes.